# Clinical Trial Landscape: 04_colorectal_kras_g12c

*Generated: 2026-01-05 06:56:17*

## Summary

- **Total Trials**: 100
- **Flagged for Review**: 0
- **Search Terms Used**: 12

## Phase Distribution

| Phase | Count | Distribution |
|-------|-------|--------------|
| Phase 1 | 27 | █████ 27.0% |
| Phase 2 | 20 | ████ 20.0% |
| Not Applicable | 16 | ███ 16.0% |
| Phase 1/Phase 2 | 13 | ██ 13.0% |
| Unknown | 11 | ██ 11.0% |
| Phase 3 | 10 | ██ 10.0% |
| Phase 4 | 1 |  1.0% |
| Phase 2/Phase 3 | 1 |  1.0% |
| Early Phase 1 | 1 |  1.0% |

## Status Distribution

- **Recruiting**: 97 (97.0%)
- **Not yet recruiting**: 2 (2.0%)
- **Enrolling by invitation**: 1 (1.0%)

## Top Sponsors

| Sponsor | Trial Count |
|---------|-------------|
| M.D. Anderson Cancer Center | 8 |
| Hoffmann-La Roche | 4 |
| Mirati Therapeutics Inc. | 4 |
| Eli Lilly and Company | 4 |
| Memorial Sloan Kettering Cancer Center | 3 |
| Amgen | 3 |
| Revolution Medicines, Inc. | 3 |
| Merck Sharp & Dohme LLC | 2 |
| University of California, Davis | 2 |
| National Cancer Institute (NCI) | 2 |
| TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Thera | 2 |
| Cancer Support Community, Research and Training In | 1 |
| Icahn School of Medicine at Mount Sinai | 1 |
| Daiichi Sankyo | 1 |
| Linnaeus Therapeutics, Inc. | 1 |

## Interventions

| Intervention | Occurrences |
|--------------|-------------|
| Pembrolizumab | 18 |
| Cetuximab | 11 |
| Pemetrexed | 11 |
| Carboplatin | 11 |
| Adagrasib | 10 |
| Cisplatin | 10 |
| Sotorasib | 9 |
| Health Telemonitoring | 6 |
| Placebo | 6 |
| Questionnaire Administration | 5 |
| Divarasib | 5 |
| Biospecimen Collection | 4 |
| Panitumumab | 4 |
| Cemiplimab | 3 |
| Entrectinib | 3 |
| Atezolizumab | 3 |
| Bevacizumab | 3 |
| Computed Tomography | 3 |
| Gemcitabine | 3 |
| Leucovorin | 3 |

## Geographic Distribution

| Country | Trial Count |
|---------|-------------|
| United States | 100 |
| Spain | 25 |
| South Korea | 24 |
| Italy | 23 |
| Australia | 23 |
| France | 22 |
| Taiwan | 18 |
| Canada | 18 |
| Germany | 18 |
| Japan | 17 |
| Netherlands | 17 |
| Poland | 17 |
| Brazil | 15 |
| Belgium | 14 |
| China | 13 |

## Search Term Provenance

| Term | Source | Confidence |
|------|--------|------------|
| KRAS G12C | manual | 1.0 |
| KRASG12C | manual | 0.9 |
| KRAS-G12C | manual | 0.9 |
| colorectal cancer | manual | 1.0 |
| KRAS G12C colorectal cancer | manual | 1.0 |
| KRAS G12C metastatic colorectal cancer | llm | 0.9 |
| KRAS G12C colorectal adenocarcinoma | llm | 0.9 |
| CRC | llm | 0.8 |
| metastatic colorectal cancer | llm | 0.8 |
| KRAS p.G12C | llm | 0.9 |
| KRASp.G12C | llm | 0.8 |
| KRAS-p.G12C | llm | 0.8 |

## All Trials

| NCT ID | Phase | Status | Sponsor | Title |
|--------|-------|--------|---------|-------|
| [NCT06964633](https://clinicaltrials.gov/study/NCT06964633) | Not Applicable | Not yet recruiting | University of Hawaii | The Ku Ola Project |
| [NCT06793215](https://clinicaltrials.gov/study/NCT06793215) | Phase 3 | Recruiting | Hoffmann-La Roche | A Phase III, Randomized, Open-Label... |
| [NCT06972667](https://clinicaltrials.gov/study/NCT06972667) | Not Applicable | Not yet recruiting | State University of ... | Interventions to Decrease Cancer In... |
| [NCT06876363](https://clinicaltrials.gov/study/NCT06876363) | Phase 1/Phase 2 | Recruiting | Ensoma | A Phase 1/2 Open-Label, Single-Asce... |
| [NCT05630794](https://clinicaltrials.gov/study/NCT05630794) | Phase 1 | Recruiting | National Cancer Inst... | Phase 1 Trial of ONC201 for Chemopr... |
| [NCT06874790](https://clinicaltrials.gov/study/NCT06874790) | Not Applicable | Recruiting | University of Califo... | Randomized Controlled Trial of a Ch... |
| [NCT06914726](https://clinicaltrials.gov/study/NCT06914726) | Not Applicable | Enrolling by invitation | HealthPartners Insti... | Randomized Trial to Improve Care of... |
| [NCT06896162](https://clinicaltrials.gov/study/NCT06896162) | Not Applicable | Recruiting | UNC Lineberger Compr... | PROGRESS: Precision Oncology Using ... |
| [NCT06881784](https://clinicaltrials.gov/study/NCT06881784) | Phase 3 | Recruiting | Revolution Medicines... | RASolve 301: Phase 3 Multicenter, O... |
| [NCT06710756](https://clinicaltrials.gov/study/NCT06710756) | Phase 1/Phase 2 | Recruiting | Perspective Therapeu... | A Phase I/IIa Image-Guided, Alpha-P... |
| [NCT06875310](https://clinicaltrials.gov/study/NCT06875310) | Phase 3 | Recruiting | Mirati Therapeutics ... | A Randomized, Double-Blind, Phase 3... |
| [NCT06917079](https://clinicaltrials.gov/study/NCT06917079) | Phase 1 | Recruiting | TheRas, Inc., d/b/a ... | A Phase 1a/1b Open-Label Study Eval... |
| [NCT06890598](https://clinicaltrials.gov/study/NCT06890598) | Phase 3 | Recruiting | Eli Lilly and Compan... | A Phase 3, Multicenter, Double-Blin... |
| [NCT06804824](https://clinicaltrials.gov/study/NCT06804824) | Phase 1 | Recruiting | Vividion Therapeutic... | A Phase 1/1b, Open-Label, Multicent... |
| [NCT06805942](https://clinicaltrials.gov/study/NCT06805942) | Not Applicable | Recruiting | IR Centers | Embolization for the Treatment of H... |
| [NCT06720987](https://clinicaltrials.gov/study/NCT06720987) | Phase 1 | Recruiting | Kumquat Biosciences ... | A Phase 1/1b, Open-label, Multicent... |
| [NCT06514794](https://clinicaltrials.gov/study/NCT06514794) | Phase 2 | Recruiting | Wugen, Inc. | A Phase 2 Study of WU-CART-007, an ... |
| [NCT06807619](https://clinicaltrials.gov/study/NCT06807619) | Phase 1 | Recruiting | Memorial Sloan Kette... | BrainMet ADePPT (Anticancer Drug Pe... |
| [NCT06695845](https://clinicaltrials.gov/study/NCT06695845) | Phase 2 | Recruiting | Jazz Pharmaceuticals | A Phase 2, Open-label, Multicenter ... |
| [NCT06588686](https://clinicaltrials.gov/study/NCT06588686) | Phase 2 | Recruiting | Vicore Pharma AB | A Randomized, Double-blind, Placebo... |
| [NCT06358430](https://clinicaltrials.gov/study/NCT06358430) | Phase 1 | Recruiting | M.D. Anderson Cancer... | Phase 1 Dose Escalation and Expansi... |
| [NCT06336590](https://clinicaltrials.gov/study/NCT06336590) | Not Applicable | Recruiting | Rutgers, The State U... | Student Exercise and Sleep Timing S... |
| [NCT06607185](https://clinicaltrials.gov/study/NCT06607185) | Phase 1 | Recruiting | Eli Lilly and Compan... | A Phase 1a/1b Study of the Pan-KRAS... |
| [NCT06625983](https://clinicaltrials.gov/study/NCT06625983) | Not Applicable | Recruiting | Massachusetts Genera... | Colorectal Cancer Screening Decisio... |
| [NCT06333951](https://clinicaltrials.gov/study/NCT06333951) | Phase 1 | Recruiting | Amgen | A Phase 1b Study Evaluating the Saf... |
| [NCT06582771](https://clinicaltrials.gov/study/NCT06582771) | Phase 2 | Recruiting | Memorial Sloan Kette... | A Phase 2 Study of First-line Sotor... |
| [NCT06412198](https://clinicaltrials.gov/study/NCT06412198) | Phase 1/Phase 2 | Recruiting | M.D. Anderson Cancer... | A Multicenter Phase 1b/2 Study of A... |
| [NCT06357182](https://clinicaltrials.gov/study/NCT06357182) | Phase 1 | Recruiting | OHSU Knight Cancer I... | A Phase Ib Investigation of the LSD... |
| [NCT06248606](https://clinicaltrials.gov/study/NCT06248606) | Phase 2 | Recruiting | Ryan Gentzler, MD | Phase II Study of Adagrasib + Stere... |
| [NCT05638295](https://clinicaltrials.gov/study/NCT05638295) | Phase 2 | Recruiting | National Cancer Inst... | A Randomized Phase II Study of AMG ... |
| [NCT06252649](https://clinicaltrials.gov/study/NCT06252649) | Phase 3 | Recruiting | Amgen | Phase 3 Multicenter, Randomized, Op... |
| [NCT06447662](https://clinicaltrials.gov/study/NCT06447662) | Phase 1 | Recruiting | Pfizer | A Phase 1 Open-Label Study of PF-07... |
| [NCT06050668](https://clinicaltrials.gov/study/NCT06050668) | Phase 2 | Recruiting | Michael C Willey | MEND Repair & Recover Clinical Tria... |
| [NCT06378398](https://clinicaltrials.gov/study/NCT06378398) | Early Phase 1 | Recruiting | University of Michig... | An Early Phase 1 Trial of Omeprazol... |
| [NCT06345729](https://clinicaltrials.gov/study/NCT06345729) | Phase 3 | Recruiting | Merck Sharp & Dohme ... | A Phase 3, Randomized, Double-blind... |
| [NCT06343402](https://clinicaltrials.gov/study/NCT06343402) | Phase 1 | Recruiting | TheRas, Inc., d/b/a ... | A Phase 1a/1b Open-Label Study Eval... |
| [NCT05961709](https://clinicaltrials.gov/study/NCT05961709) | Phase 2 | Recruiting | M.D. Anderson Cancer... | The Phoenix Trial: Phase II Trial o... |
| [NCT06265285](https://clinicaltrials.gov/study/NCT06265285) | Phase 2 | Recruiting | Mayo Clinic | Pilot Single-Arm, Pragmatic Trial o... |
| [NCT06249282](https://clinicaltrials.gov/study/NCT06249282) | Phase 1 | Recruiting | City of Hope Medical... | A Phase I Clinical Trial of Carfilz... |
| [NCT06253871](https://clinicaltrials.gov/study/NCT06253871) | Phase 1 | Recruiting | Iambic Therapeutics,... | A Phase 1/1b Study of IAM1363 in Pa... |
| [NCT05853575](https://clinicaltrials.gov/study/NCT05853575) | Phase 2 | Recruiting | Mirati Therapeutics ... | A Randomized Study of Two Dosing Re... |
| [NCT06244771](https://clinicaltrials.gov/study/NCT06244771) | Phase 1/Phase 2 | Recruiting | Frontier Medicines C... | An Open-Label, Phase 1/2 Dose Escal... |
| [NCT06130254](https://clinicaltrials.gov/study/NCT06130254) | Phase 1 | Recruiting | M.D. Anderson Cancer... | Phase Ib Trial of the KRAS G12C Inh... |
| [NCT06229860](https://clinicaltrials.gov/study/NCT06229860) | N/A | Recruiting | University of Califo... | Impact of Personality on Adherence ... |
| [NCT06162221](https://clinicaltrials.gov/study/NCT06162221) | Phase 1/Phase 2 | Recruiting | Revolution Medicines... | A Platform Study of RAS(ON) Inhibit... |
| [NCT06119581](https://clinicaltrials.gov/study/NCT06119581) | Phase 3 | Recruiting | Eli Lilly and Compan... | SUNRAY-01, A Global Pivotal Study i... |
| [NCT06040762](https://clinicaltrials.gov/study/NCT06040762) | Not Applicable | Recruiting | University of Washin... | The "Get Moving Trial": A Phase I/I... |
| [NCT05920356](https://clinicaltrials.gov/study/NCT05920356) | Phase 3 | Recruiting | Amgen | A Phase 3, Multicenter, Randomized,... |
| [NCT06128551](https://clinicaltrials.gov/study/NCT06128551) | Phase 1 | Recruiting | Revolution Medicines... | Phase 1b, Multicenter, Open-Label, ... |
| [NCT06403436](https://clinicaltrials.gov/study/NCT06403436) | Phase 1 | Recruiting | TOLREMO therapeutics... | A Phase 1, First-in-Human, Open-lab... |

*... and 50 more trials (see trials.csv for full list)*
